UCB stock trades at EUR 205.70, 29.0 percent below its 52-week high

Published on 10/12/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock trades at EUR 205.70 on October 12, 2026, 0.48 percent below the Xetra close. The 52-week high is EUR 289.50.

Key points in brief

UCB stock traded at EUR 205.70 at Lang & Schwarz on October 12, 2026, minus 0.48 percent versus the Xetra close of October 9, 2026.
The price stood 28.96 percent below the 52-week high of EUR 289.50.
UCB had a market capitalization of EUR 39.2 billion and a P/E ratio of 17.79 as of October 12, 2026.
UCB's first-half 2026 product figures included BIMZELX sales of EUR 1.52 billion and FINTEPLA sales of EUR 239.0 million.

Aquarellmalerei der Brüsseler Skyline mit historischen Türmen und modernen Bürotürmen bei Sonnenuntergang — UCB S.A., ISIN BE0003739530, dargestellt durch stimmungsvolles Aquarell der Brüsseler Skyline bei Sonnenuntergang, Illustration mit AI erstellt.

UCB stock (ISIN BE0003739530) was trading at EUR 205.70 at Lang & Schwarz on October 12, 2026 at 1:19 p.m. CEST, minus 0.48 percent versus the Xetra close of October 9, 2026 at EUR 206.70. The move places the price 28.96 percent below its 52-week high of EUR 289.50.

Price sits below yearly high

The intraday quote was supported by a bid of EUR 205.60 and an ask of EUR 205.80 at Lang & Schwarz at 1:19 p.m. CEST. Trading volume on Euronext Brussels was 26,742 shares as of October 12, 2026, compared with an average volume of 231,704 shares.

UCB is listed on Euronext Brussels under ticker UCB and ISIN BE0003739530, according to Nova Pharma News on October 11, 2026. The 52-week range from the market quote is EUR 146.05 to EUR 289.50, leaving the current price 40.85 percent above the low.

Valuation and product sales

UCB had a market capitalization of EUR 39.2 billion and a P/E ratio of 17.79 as of October 12, 2026. The valuation measure gives the price report a second frame beyond the daily move, because the stock remains closer to its yearly low than its yearly high.

UCB's investor page lists BIMZELX sales of EUR 1.52 billion in the first half of 2026, FINTEPLA sales of EUR 239.0 million and RYSTIGGO sales of EUR 192.0 million. The same page lists BIMZELX peak sales guidance above EUR 7.0 billion, making the product portfolio a central valuation reference for the biopharmaceutical company.

Comparison with peers

UCB: minus 0.48 percent, P/E 17.79, market capitalization EUR 39.2 billion

GSK plc (LSE, GBp): plus 0.86 percent, P/E 14.83, market capitalization GBP 70.7 billion

Novartis AG (NYSE, USD): plus 0.45 percent, P/E 21.94, market capitalization USD 273.2 billion

Current trading perspective

The comparison shows UCB trading between the selected peers on valuation, with a P/E below Novartis and above GSK. For investors, the key market markers are the EUR 206.70 Xetra close, the EUR 289.50 yearly high and the EUR 39.2 billion market capitalization.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.